ORIC Reports Data Supporting Rinzimetostat in Prostate Cancer

ORIC Pharmaceuticals said preclinical and translational data suggest rinzimetostat may enhance sensitivity to androgen receptor inhibition. The findings support further study across disease settings and in its ongoing Himalayas-1 Phase 3 trial.